NEW YORK, NY / ACCESS Newswire / April 4, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
NEW YORK, NY / ACCESS Newswire / April 4, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn ...
Recent market volatility notwithstanding, equities generally deliver solid returns over long periods, like a decade. The key ...
Defendants' statements included, among other things, confidence in Merck's purported ability to utilize successful consumer activation and education efforts on the benefits of Gardasil in order to ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the new Donald Trump administration. Health care stocks can often be a solid defensive play in an uncertain economy.
Merck (NYSE:MRK) recently presented promising results from the Phase 3 ZENITH trial for its drug WINREVAIR, but the company's stock performance over the past month tells a different story, declining ...
Learn more about whether Jazz Pharmaceuticals plc or Merck & Co., Inc. is a better investment based on AAII's A+ Investor ...
On July 30, 2024, Merck released its second quarter 2024 financial report and disclosed a significant reduction in Gardasil vaccinations, resulting in an overabundance of inventory at Merck's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results